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ABSTRACT
Introduction In breast surgeries, prophylactic antibiotics
given before the surgical incision as per Joint Commission
Surgical Care Improvement Project guidelines have been
shown to decrease the rate of postoperative infections.
There is, however, no clear consensus on postoperative
antibiotic prophylaxis in patients undergoing mastectomy
with indwelling drains. This trial protocol proposes to
study the difference in rates of surgical site infection (SSI)
with or without continuation of postoperative antibiotics
in patients undergoing mastectomy without immediate
reconstruction and with indwelling drains.
Methods and analysis In this multicentre, double-
blinded clinical trial, all patients undergoing mastectomy
(without immediate reconstruction) will receive a
single prophylactic dose of preoperative antibiotics at
induction of anaesthesia and will then get randomised
to either continue antibiotic prophylaxis or a placebo
postoperatively, for the duration of indwelling drains. The
primary and secondary outcomes will be development
of an SSI and antibiotic-associated adverse effects,
respectively. Data will be collected through a standard
questionnaire by wound assessors. Intention-to-treat
analysis will be carried out using STATA V.12. For
categorical variables, frequencies and percentages will be
assessed by χ2 test/Fisher’s exact test as appropriate. The
quantitative variables will be computed by their mean±SD
or median (IQR) and will be assessed by independent t-
test/Mann-Whitney test as appropriate. Unadjusted and
adjusted relative risk with their 95% CI will be reported
using Cox proportional regression. A p value of <0.05 will
be considered statistically significant.
Ethics and dissemination Ethical approval has been
obtained from each site’s Ethical Review Board. The

Strengths and limitations of this study
►► A pragmatic, multicentre, double-
blinded, ran-

domised control trial conducted at public and private
tertiary care hospitals.
►► Patients with comorbidities will not be excluded unless there is an absolute need for antibiotics postoperatively, thus results will be generalisable.
►► Patients in this study are randomised using the
block-randomisation technique due to which treatment groups are equal in size and are uniformly distributed as related to patient characteristics.
►► The trial excludes patients undergoing immediate
reconstruction as this procedure is not a commomly
performed procedure in the developing world.
study background and procedure will be explained to the
study participants and informed consent will be obtained.
Participation in the study is voluntary. All data will be
deidentified and kept confidential. The study findings will
be published in scientific media and authorship guidelines
of International Committee of Medical Journal Editors will
be followed.
Trial registration number NCT04577846. (patient
recruitment)

INTRODUCTION
Background
Worldwide, breast cancer comprises 10.4%
of all cancer among women, making it the
second most common cancer (after lung
cancer) and the fifth most common cause
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of cancer death. In Pakistan, breast cancer is the most
common malignancy in women, accounting for approximately 40% of all malignant tumours. A study from
Pakistan conducted at a tertiary care hospital reported
that regardless of age, the majority of patients in their
cohort presented with higher stage breast cancer than
the comparison group of patients in the National
Cancer Database, which is a hospital registry US database of over 1500 cancer centres.1 The higher stage
at presentation often leads to a greater likelihood of
warranting a mastectomy rather than breast conservation surgery.
Reports of surgical site infections (SSIs) after breast
surgery may range from 1% to 26%,2–5 which is high
for surgeries that are considered ‘clean procedures’, as
defined by the Centers for Disease Control and Prevention (CDC) wound classification system. There is no clear
consensus on the duration of prophylactic antibiotics in
patients undergoing mastectomy, and practices may vary
among breast and reconstructive surgeons. Prophylactic
antibiotics given before surgical incision/procedures
as per Joint Commission Surgical Care Improvement
Project guidelines have been shown to decrease the rate
of postoperative infections in a vast number of patients.
However, the efficacy of prophylactic antibiotics used
after surgeries is not known.6–9 Therefore, most guidelines recommend a single dose of periprocedural antibiotics, and prolonged continuation after surgery has
been discouraged. The use of common or more specific
antibiotics for the duration of drains being in place is
controversial.
The drains used following breast surgeries are closed
suction, and they are retained for a variable duration
depending on the volume of effluent. The likelihood of
microorganisms contaminating these drains increases
with longer presence and may result in SSI, yielding
the same organisms as found in the drains.4 9 Evidence
regarding the risk of SSI with the use and duration of
indwelling drains is controversial.4 9–15 Surgical drains are
commonly removed when output is less than 30 mL/24
hours, often 5–7 days later; however, some patients can
have drains in place for weeks before meeting the criteria
for removal.16
Recent national/international clinical guidelines
recommend the use of a single dose of preprocedural
antibiotics for mastectomy patients with or without
drains.17 18 The American Society of Breast Surgeons also
does not recommend the continuation of postsurgical
antibiotics in the absence of relevant indicators, such as
purulent drainage from the incision or drain site, tenderness, localised swelling, erythema or warmth, and clinical
diagnosis of cellulitis.19 Even in the setting of immediate
breast reconstruction following mastectomy, there is
insufficient evidence for the use of extended prophylactic
antibiotics to reduce SSI rates. However, the meta-analysis
also pointed out that, in general, antibiotics were not
used uniformly in terms of regimens, timing, dosing, and
duration.20
2

Lack of clear consensus and absence of universal guidelines regarding postoperative continuation of prophylaxis
results in significant practitioner variation. In a study by
Brahmbhatt et al,21 16% of practitioners reported that,
most of the time, they use postoperative antibiotics as
prophylaxis; in contrast, 76% responded that they never
use postsurgical prophylaxis for more than 24 hours in
patients without reconstruction. The length of prolonged,
postoperative antibiotics may also vary by practitioners,
some using a predefined regimen of about 2–7 days while
others continue them until the drains are removed.
Rationale
There is no clear consensus regarding the continuation
of postoperative antibiotic prophylaxis following breast
surgeries, consequently significant practitioner variation
exists globally. Various studies have failed to establish the
impact of postoperative antibiotic prophylaxis on rates of
SSIs, thus a prospectively designed phase III clinical trial
is essential to provide higher level evidence. We propose
to study the difference in rates of SSI in a double-blinded,
multicentre trial by randomising patients undergoing
mastectomy (without immediate reconstruction and with
indwelling drains) to be randomised to either continuing
prophylactic antibiotics or receiving a placebo postoperatively. All will receive a single dose of prophylactic antibiotic preoperatively.
Objectives
1. To determine the rates of SSI in patients in the two
arms of this trial, in which all patients will receive the
first prophylactic preoperative antibiotic dose at induction of anaesthesia and then be randomised to:
a. Receive a placebo every 8 hours, as long as there is/
are drains(s) in place.
b. Continue receiving prophylactic antibiotic every 8
hours for the duration of indwelling drains.
2. To identify factors associated with differing rates of SSI
in the intervention and control group.
Trial design
This is a two-armed, randomised, double-blinded placebo
control clinical trial. The study participants will be
women, 18 years and older, who are planned to undergo
mastectomy without immediate reconstruction and will
have indwelling closed suction drain(s). We used the
Standard Protocol Items: Recommendations for Interventional Trials checklist when writing this protocol.22

METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOME
Study setting
This study will be conducted at three sites:
Site 1: Aga Khan University Hospital (AKUH), Karachi,
Pakistan, a tertiary care private hospital.
Site 2: Liaquat National Hospital (LNH), Karachi, Pakistan, a tertiary care private hospital.
Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572
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Site 3: DOW University of Health Sciences (DUHS),
Karachi, Pakistan, a public sector hospital.
Eligibility criteria
Inclusion criteria: this trial will include all the patients
who are:
►► Women, 18 years and older, who are planned for
mastectomy by a breast surgeon at one of the study
sites, that is, AKUH, LNH or DUHS, and who will have
indwelling closed suction drain(s) postoperatively.
►► Women who will give consent to participate in the
study.
Exclusion criteria: this study will exclude all those
patients who will:
►► Undergo immediate breast reconstruction. The
healthcare payment model in the developing world,
including Pakistan, is fee-
for-
service in which a
patient pays for each individual medical care service,
including reconstruction. Subsequently, reconstruction is an expensive procedure, which poses a huge
financial burden for a majority of patients. Additionally, locally advanced breast cancer is more prevalent
in our setting than the developed world in the West,
warranting postmastectomy radiation, which often
leads us to recommend delayed reconstruction as the
preferred option. Thus, most patients who undergo
mastectomy either do not elect or are not ideal candidates for immediate reconstruction.
►► Have other medical indications for which they must
remain on antibiotics for more than the single preoperative dose.
►► Have any history of allergies to beta-lactam drugs or
iodine.
►► Had an open breast or axillary biopsy/breast conservation in the last 30 days on the ipsilateral side.
Interventions: description, modifications and adherence
Description
Treatment arm
Standard care 1 g intravenous cefazolin given preoperatively at induction of anaesthesia followed by a course of
500 mg oral cephalexin given every 8 hours for the duration of the indwelling drains.
Control arm
Standard care 1 g intravenous cefazolin given preoperatively at induction of anaesthesia followed by a course of
oral placebo capsules (identical in physical appearance to
the antibiotic) given every 8 hours for the duration of the
indwelling drains.
The investigational product will be stored in the Clinical Trial Unit (CTU) research pharmacy with controlled
access under the direct supervision of the CTU pharmacist. The CTU pharmacist in the presence of the study
team personnel will verify the expiry and lot/batch
number at the time of receiving. The expiry date and the
batch number will be documented in the pharmacy logs
(investigational product/supplies inventory and expiry
Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572

log). All unused investigational products collected from
patients will be returned to the CTU pharmacy. The CTU
pharmacist will also keep track of inventory and will notify
the principal investigator and study coordinator when the
investigational product (IP) needs to be restocked.
Study flow
Three research assistants, one for each site, are medical
and dental graduates (with experience of facial wounds),
who would be trained in the Centre for Disease Control
(CDC) wound assessment criteria for SSIs by the principle investigator (PI) and the co-
PI (an infectious
disease specialist) over a 2-week period prior to initiating
the trial. Research assistants would also be required to
shadow the PI in the clinics for a week to have uniform
training regarding wound assessment, before initiation
of the trial. Also, a research coordinator will liaise with
the research assistants and will be coordinating the study
at all three sites. The research coordinator will ensure
an adequate supply of the study drug as well as placebo
prepared by the AKUH pharmacy to be dispensed to the
CTUs of respective institutions. At each of the three sites,
a consistent approach to monitoring/documentation of
SSI as well as adverse outcomes will be ensured by the
research team.
All patients who are consented and booked for mastectomy (without reconstruction) by the participating
surgeons of AKUH, LNH and DUHS will be screened
by trained research assistants during the outpatient
preoperative clinic visit (online supplemental appendix
1). The eligible and consented participants will then be
randomised preoperatively by the CTU pharmacist (as
above) using a computer-generated randomisation list, to
either the intervention or control arm.
At the time of surgery, standardised skin preparation
will be performed for both arms before the incision by
the surgical team. The prep will consist of:
1. Povidone iodine 0.75 % W/V with normal saline hand
scrub.
2. Iodine preparation paint.
3. Cefazolin 1 g intravenous preoperatively at the induction of anaesthesia.
Postsurgery
1. The intervention arm will be administered oral cefalexin 500 mg every 8 hours, which will be continued
for the duration of the indwelling drains (usually 14
days).
2. The control arm will be administered an identical in
appearance placebo capsule filled with inert material
for the duration of the drains.
3. All study medications, that is, antibiotic/placebo, will
be dispensed by the CTU pharmacist.
Wound assessment
1. SSI will be assessed by the treating surgeon and the
wound assessor (trained research assistants) during the
follow-
up visits. The research assistants will be doing
3
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their independent wound assessment without being influenced by the surgeon. The data collection form has
separate areas to document findings of surgeons as well
as the wound assessor for independent evaluations.
2. The first postoperative visit will be on postoperative
day 5±2 days (3–7 days) and subsequently at each routine postoperative visit while the drain is in place. As
per CDC guidelines, the day of the procedure will be
considered postoperative day 1. Rates of SSI will be
collected up to the 90th postoperative day. If the patient does not have a routine clinic visit scheduled on
day 90, the wound assessor (trained research assistant)
will call the patient over the phone to inquire about
the status of the wound. If need be, the patient will be
asked to come in for a wound evaluation.
3. Rates of drug-
related adverse effects will be
documented.
Data will also be collected on the patient’s clinical
factors potentially relevant to SSI, including smoking
status (as never smoker, prior smoker and patients who
quit smoking within the last 60 days before surgery),
patient’s age, body mass index (BMI; >30 is defined as a
marker of obesity) diabetes mellitus and recent corticosteroid use (inhaled/oral), prior ipsilateral breast/axillary
surgery in the last 60 days, neoadjuvant chemotherapy,
prior radiation to the ipsilateral breast and patients with
active tuberculosis, HIV or on immunosuppression. Data
will also be abstracted on the type of surgery performed
defined as:
a. Unilateral/bilateral mastectomy.
b. Associated axillary surgery (none, sentinel lymph node
biopsy, axillary sampling or axillary dissection).
c. The procedural length will be recorded in minutes
from the start of incision to completion of skin closure.
d. Type of skin closure (staples vs subcuticular).
e. Duration of drain retention (counting day of surgery
as day 1).
f. Duration of hospital stay, counting the day of admission as day 1.
g. Other constant variables will be additionally evaluated as dichotomous categorical variables, that include
BMI >30, hospital stay >1 day, drain duration >14 days
and having more than one drain in situ. Length of the
stay >1 day is selected for comparison as most of our
patients are discharged the day after the procedure at
our institute. Age will be additionally evaluated categorically by decade (online supplemental appendix 2).
Modification
Discontinuation from the study
1. Any adverse effects as perceived (by the treating surgeon) to be related to the study drug. This includes,
but is not limited to, rash and diarrhoea.
2. Development of a wound infection while on the study
drug (the patient will exit the study and the infection
will be treated and counted as the outcome).
3. Need for reoperation on the same site within 30 days
of the mastectomy (except for when reoperation is for
4

infection, in which case the patient will exit the study,
but the infection will be counted as the outcome).
Adherence
Subject compliance will be monitored by the CTU pharmacist, by counting the returned study drug/capsules as
well as by reviewing the compliance log maintained by the
patient. An additional compliance log will be maintained
by the primary investigator/study team after a reminder
telephone call to the participants in each group. This
phone call will be made to reinforce the instructions and
the need to maintain the log, as well as for reassurance.
(online supplemental appendix 3).
Outcomes
Primary outcome: SSI (time frame: up to 90 days).
Standard CDC criteria:23
1. Purulent drainage from the incision or drain site.
2. Organisms isolated from an aseptically obtained culture of fluid or tissue.
3. Deliberate opening of the incision by a surgeon in patients having either tenderness, localised swelling, redness or warmth.
4. Diagnosis of SSI by the surgeon or study wound assessor.
5. Prescription of therapeutic antibiotics.
6. Patients clinically diagnosed and documented to have
cellulitis.
Other outcome measures
Rates of antibiotic-associated side effects (time frame: will
be assessed during the follow-up visits between postoperative days 3 and 7 for the first postoperative visit and subsequently at each routine postoperative visit while the drain
is in place, for a maximum of 90 days).
Participant timeline
Patients will be enrolled preoperatively, after consenting
to the surgical procedure. Research assistants will screen/
consent the patient and liaise with the CTU to arrange
for the relevant study drug. All study patients (in both
arms) will receive the preoperative antibiotic prophylaxis
at the time of induction. The postoperative antibiotic/
placebo doses will be administered to the patient at an
interval of 8 hours and will continue for the duration
of the indwelling drains. Patients will be followed for 90
postoperative days, counting the day of the surgery as day
1. At each follow-up visit, the patient will be assessed both
by the primary surgeon/another covering study surgeon
as well as the wound assessor (trained research assistant).
Over the phone, follow-ups will be done by the wound
assessor (trained research assistant) only.
Sample size calculation
The sample size was calculated in OpenEpi software
V.3.01. The minimum sample size that will be required
is 384 patients who have undergone mastectomy with
indwelling drains. Of these, 192 patients will be those
with a single dose of prophylactic preoperative antibiotic
Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572
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and prolonged use of prophylactic postoperative oral
antibiotics (intervention arm), and 192 participants will
be those with a single dose of prophylactic preoperative
antibiotic with placebo (control arm), with inflation of
10% in both the groups for non-response rate. An anticipated incidence of surgical site infection (SSI) of 3.4%
in the intervention arm and 9.2%–14% in the control
arm,4 24 with a 5% level of significance and power of 80%
to detect a 9% reduction of infection in intervention arm
versus the control. Since we will be recruiting participants
from three study sites, we applied proportionate sampling
to estimate the sample size for each group. In this technique, the sample size of each site is proportionate to
the total population size, which was 565. We calculated
the per cent (weight) for each group by taking a ratio of
the number of individuals in each group and the total
population. Hence, we will require a minimum sample
of 66 women in the intervention arm and 66 women in
the control arm from AKU, 85 women in the intervention
arm and 85 women in the control arm from LNH, and 41
women in the intervention arm and 41 women in control
arm from DUHS campus.

METHODS: ASSIGNMENT OF INTERVENTIONS (CONTROLLED
TRIAL)
Allocation: sequence generation, concealment mechanism
and implementation
The PI’s research fellow will serve as the research coordinator and will be responsible for coordination with
the specially hired and trained wound assessors/trained
research assistants. At each of the three study sites, the
research assistants will be responsible for recruiting
participants, obtaining the study drug from the CTU
and delivering it to the patient, giving instructions and
following up on the wound status as well as for study drug
compliance. The research assistants will receive adequate
training from the principal investigator.
Randomisation will be performed by the block randomisation method. Patients will be allocated to one of the
following groups:
Group 1 (intervention arm): will be those patients who
will receive a single dose of prophylactic preoperative
antibiotic (cefazolin 1 g intravenously preoperatively),
then continue with oral cefalexin (capsule) 500 mg every
8 hours, for the duration of the drains, which usually is
about 14 days.
Group 2 (control arm): will be those who receive a single
dose of prophylactic preoperative antibiotic (cefazolin 1
g intravenously preoperatively). Postoperatively, these
patients will receive a capsule filled with inert material
every 8 hours (placebo capsule, which will be identical in
appearance to the study antibiotic).
Randomisation will be performed via computer-
generated random numbers by the AKUH CTU
pharmacy.
Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572

Blinding (masking)
This study is a double-
blinded randomised controlled
trial as our participants and the treating surgeon/wound
assessor (trained research assistant) will be blinded to
the group that each participant will be assigned to. As an
additional measure to maintain blinding, both the study
antibiotic and placebo will be dispensed by the CTU in
capsules that have an identical appearance.
Blinding (masking): emergency unblinding
Unblinding can be done in the following situations:
1. Accidental unblinding.
2. Unblinding due to any serious adverse event (SAE).
In either case, the principal investigator will promptly
document and explain any unblinding to the sponsor and
the Ethics Review Committee (ERC). If a patient’s treatment assignment is unblinded, the patient will remain in
the study and continue the protocol-specified follow-up
evaluations.

METHODS: DATA COLLECTION, MANAGEMENT AND ANALYSIS
Data collection plan
The outcome assessment (SSI) will be performed by
the treating surgeon and the wound assessor (trained
research assistant) during the follow-up visits. The data
on the patient’s demographics and other disease-related
information will be collected on a structured questionnaire. The data collection form can be made available
from the corresponding author on reasonable request.
Data collection plan: retention
All this information will be maintained at the CTU AKUH.
Data management
The data will be entered in Redcap software. The data
will be double entered and range checks will be entered
to maintain the quality of the data. The database is authorised only to the principal investigator. The database can
be made available from the corresponding author on
reasonable request.
Statistics: analysis population and missing data
We plan to do the intention-to-treat analysis as mentioned
in the plan of analysis. The missing data will be dealt with
by imputation. The analysis will be performed using
STATA V.12. Descriptive statistics will be computed for
categorical variables by computing their frequencies
and percentages and will be assessed by χ2 test/Fisher’s
exact test as appropriate. The quantitative variables will
be computed by their mean±SD or median (IQR) and
will be assessed by independent t-
test/Mann-
Whitney
test as appropriate. Unadjusted and adjusted relative risk
with their 95% CI will be reported by using Cox proportional regression. All plausible interactions will also be
assessed. Intention-to-treat analysis will be carried out. A
p value of <0.05 will be considered statistically significant
throughout the study.
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METHODS: MONITORING
Data monitoring: formal committee
The data monitoring team of AKUH CTU (principal site)
will overlook the trial. This data monitoring committee
overlooks all the trials that take place at the Aga Khan
University and is independent of the sponsors. Further
details of its key services and ancillary services can be
found
online
(https://www.aku.edu/ctu/services/
Pages/home.aspx).
Data monitoring: interim analysis
The data and safety monitoring committee, composed of
an independent group of experts in the involved fields
(biostatistician, clinical researcher, epidemiologist and
a clinician with expertise in the disease under investigation), will conduct an interim analysis. If significantly
high rates of SSI in one group compared with the other
at interim analysis is observed, the trial will be stopped.
Harms
Adverse events
In the event of an adverse effect, study participants will be
instructed to report to their treating surgeon immediately.
The primary surgeon will then assess if the symptoms are
an adverse drug effect and recommend withdrawal from
the study if deemed so. The anticipated drug adverse
could be events, such as a drug allergy, Clostridium difficile
or antibiotic-associated diarrhoea. Only <5% of patients
develop allergy due to cephalosporin use; similarly, there
is inconsistency regarding the relationship of C. difficille-
associated diarrhoea with cephalosporin use.25–27 Investigations pertaining to the adverse drug effect may include,
but are not limited to, complete blood counts and stool
test (for suspected C. difficille). The adverse events (AEs)
will be recorded and reported to ERC within a specified
period. A patient thought to have an adverse reaction
will exit the trial at this point. Management given for the
AE/SAE will be documented in the study documents.
All drug accountability will be maintained in the CTU.
If the patient is withdrawn from the study, they will be
encouraged to complete the follow-up visits and data will
be collected for the follow-up visit.
Assessment of safety
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical
product and which does not necessarily have a causal relationship with this treatment will also be documented. An
AE can, therefore, be any unfavourable and unintended
sign (including an abnormal laboratory finding), symptom
or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to
the medicinal (investigational) product. All study-related
adverse/serious AEs will be managed and reported to the
ERC, medical affairs and pharmacy. The principal investigator and study coordinator will follow-up on any AEs and
SAEs. The type and duration of the follow-up of subjects
after AEs will be defined by the PI.
6

Reporting and recording of procedures of adverse events
The PI will report all AEs in case report form (CRF)/
Data Clarification form (DCF), AE reporting form to
the sponsor (in the specified time) and to the ERC.
SAE will be reported to the sponsor via telephone,
email, and/or fax within 24 hours. Confirmation will be
ensured and documented. The immediate report will
be followed by a detailed written report on the event
and SAE/AE form along with supporting documents
will be submitted to the study sponsor and ERC no later
than 7 days from notification of the event. The PI will
also report to relevant authorities within 15 calendar
days after SAE/unanticipated AE that may be related to
the study protocol. The PI will also be responsible for
reporting all serious or unexpected AE to ERC within 7
days from notification of the event. Requests from the
sponsor/ERC for further information of the SAE will be
promptly responded to.
Patients will be withdrawn from the study due to:
1. Withdrawal of consent by the patient or legal guardian.
2. Development of any AE or SAE.
3. Investigator decision that, in the interest of the patient,
it is not medically acceptable to continue the patient’s
participation in the study.
4. Termination of the study by the sponsor.
If the patient withdraws from the study, the principal
investigator will promptly document and inform the
sponsor about the termination from the study within 48
hours. Despite withdrawing from the study, patients will
be encouraged to complete the follow-up visits and data
will be collected for the follow-up visit. Participants who
will withdraw or will be terminated from the study will not
be replaced as the sample size is calculated keeping in
view the 10% non-response rate.
Auditing
The audit of the trial is usually conducted by the ERC
(and sometimes by Joint Commission International) who
are independent from the investigators and the sponsors.
Ethics and dissemination
Research ethics approval
Ethical approval has been obtained from the ERC of all
three study sites that is, the Aga Khan University, Karachi’s ERC, and ERC at LNH and DUHS. The study will be
conducted according to the Consolidated Standards of
Reporting Trials guidelines (figure 1) and guidelines of
the World Medical Association’s Declaration of Helsinki
and the principles of Good Clinical Practice (GCP).
The study background and procedure will be explained
to the study participants and informed consent will be
obtained. Participation in the study is voluntary. All
data will be deidentified and will be kept confidential.
The study findings will be published in the scientific
media and the authorship guidelines of International
Committee of Medical Journal Editors (ICMJE) will be
followed.
Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572
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Assessed for eligibility
(n = …)

Enrollment

Allocation:
Patients

Randomized (n = ….)

Allocated to intervention arm (n =)
Received allocated intervention (n =)
Did not receive allocated intervention
(give reasons) (n = …)

Follow up: Patients

Analysis: Patients

Excluded (n = …
- Not meeting inclusion
criteria (n = …)
- Refused to participate (n =
…)
- Other reason (n = …)

Allocated to control arm (n =)
Received allocated treatment (n =)
Did not receive allocated treatment
(give reasons) (n = …)

Lost to follow-up (give
reason) (n = …)

Lost to follow-up (give
reason) (n = …)

Discontinued intervention
(give reasons) (n = …)

Discontinued intervention
(give reasons) (n = …)

Analyzed (n = …)

Analyzed (n = …)

Excluded from analysis (give
reasons) (n = …)

Excluded from analysis (give
reasons) (n = …)

Figure 1 Consolidated Standards of Reporting Trials 2010
flow diagram.

Protocol amendments
Any amendment in protocol will be submitted to the ERC
and regulatory authorities for approval, and the trial will
be conducted in compliance with regulations reporting,
6-month/annual safety and progress reports, and a copy
of the final study report will be submitted to the ERC and
funding agency.
Consent or assent
Participants will be recruited from AKUH, LNH and
DUHS. Written informed consent will be obtained from
the participants by trained research assistants/data
collectors (online supplemental appendix 4). They will
be explaining the study procedure in detail to the study
participants along with the risks and benefits associated
with taking part in the study. The data collectors will be
trained by the PI and co-investigators. Randomisation for
all study sites will take place at the CTU AKUH.
Confidentiality
Strict confidentiality and privacy rules will be followed.
Patients will be informed that all information will be kept
confidential. All study materials containing personal identifiers will be kept in a locked file cabinet. A unique study
identification number will be assigned to each participant. Data will be entered from the hard copy into the
electronic database that will be password protected and
only accessed by the research staff of this study. As per
GCP guidelines, data will be retained for 15 years. The
participation of the participants will be voluntary.

presentations at conferences and workshops, and research
briefs.
Dissemination policy: authorship
We will follow the authorship guidelines of ICMJE for
authorship eligibility. At the moment, we do not intend
to use any professional writers. However, if the journal
suggests reaching out to English proofreading experts,
we will seek professional assistance.
Dissemination policy: reproducible research
Materials that are described in this manuscript pertain to
the study protocol and no raw data is being reported. The
data set will be collected and analysed and can be made
available from the corresponding author on reasonable
request.
Patient and public involvement
It was not possible to involve patients or the public in the
design, or conduct, or reporting, or dissemination plans
of our research.
Strengths and limitations of the study
First, this will be a multicentre study, including both public
and private tertiary care hospitals catering to patients
from different socioeconomic backgrounds. Hence,
our study results will be generalisable to all mastectomy
patients who have drains in place and have not undergone reconstruction. Moreover, to the best of our knowledge, this will be the first study from our context. Finally,
the pragmatic approach will allow easy applicability to the
current practice of individuals across a wide range of clinical settings. One of the limitations of our study is that
patients with reconstruction will be excluded to prevent
variability in outcomes.
Study implications
Through this study, we will be able to identify the most
effective prophylactic regimen to reduce rates of SSI
among mastectomy patients with indwelling drains, hence
it will lead to informed decision-making. The results will
be widely generalisable and applicable worldwide.
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